Soligenix to Present New HyBryte Data for Cutaneous T-Cell Lymphoma Treatment at USCLC Workshop

Soligenix Inc. announced that new supportive trial data for HyBryte in the treatment of cutaneous T-cell lymphoma will be presented at the United States Cutaneous Lymphoma Consortium Workshop on March 26, 2026, ahead of the American Academy of Dermatology Annual Meeting. The presentations will highlight positive results from a long-term treatment study and a comparative analysis versus Valchlor, supporting HyBryte's potential as a therapeutic option for CTCL. This development is significant as cutaneous T-cell lymphoma represents a rare disease with limited treatment options, and new therapeutic approaches are needed to address unmet medical needs in this patient population.

The company's Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma. With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. The upcoming presentation of new data at the USCLC Workshop provides an important opportunity for the medical community to review the latest clinical evidence supporting this treatment approach. The comparative analysis versus Valchlor is particularly noteworthy as it may demonstrate relative advantages of the HyBryte treatment modality in clinical practice.

Development programs in this business segment also include expansion of synthetic hypericin into psoriasis, the company's first-in-class innate defense regulator technology, dusquetide for the treatment of inflammatory diseases including oral mucositis in head and neck cancer, and another compound in Behcet's Disease. The Public Health Solutions business segment includes development programs for RiVax, the company's ricin toxin vaccine candidate, as well as vaccine programs targeting filoviruses such as Marburg and Ebola and CiVax, the vaccine candidate for the prevention of COVID-19. The development of these vaccine programs incorporates the use of the proprietary heat stabilization platform technology known as ThermoVax.

This business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency and the Biomedical Advanced Research and Development Authority. The latest news and updates relating to Soligenix are available in the company's newsroom at https://ibn.fm/SNGX. The presentation of new HyBryte data represents an important milestone in the development pathway for this potential treatment, coming at a time when the company is preparing for regulatory submissions and potential commercialization. For more information about the specialized communications platform covering this sector, visit https://www.BioMedWire.com.